Lindsey Byrne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lindsey Byrne has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Helmy Abdel-Rahman
Havener Eye Institute, Department of Ophthalmology and Visual Sciences, The Ohio State University Wexner Medical Center, Columbus, USA
8 shared publications Isabella Gray
Havener Eye Institute, Department of Ophthalmology and Visual Sciences, The Ohio State University Wexner Medical Center, Columbus, USA
4 shared publications- Joseph McElroy
Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA
4 shared publications - Colleen M. Cebulla
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus Ohio USA
3 shared publications Emma Schreiner
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus Ohio USA
3 shared publicationsJenna Wolfe
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus Ohio USA
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1) , 410
Ovarian sex cord-stromal tumors are part of the BAP1-tumor predisposition syndrome: evidence from human carriers and mouse models
- 21 October 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1) , 410
Open AccessOvarian sex cord-stromal tumors are part of the BAP1-tumor predisposition syndrome: evidence from human carriers and mouse models
- Open Access
- 7 July 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (4) , e70108
Impact of Multigene Panel Testing in High‐Risk Uveal Melanoma Patients
Germline genetic testing is increasingly incorporated into the care of patients with uveal melanoma, yet optimal testing strategies remain unclear. This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021 and 9/19/2025. Seventy individuals underwent clinical genetic testing, primarily via large multigene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes ( BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2 ). Among unrelated individuals, the positive rate was 13% (8/69). Excluding carrier genes, the rate was 10.1% (7/69). Eight patients would have been missed if only tested for BAP1 per American Society of Clinical Oncology (ASCO) 2024 recommendations. There was no association between tumor size, stage, and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, these findings support genetic counseling for multigene panel testing in high‐risk uveal melanoma patients. Further studies of the impact of germline variants on UM disease outcome are warranted.
- 7 July 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (4) , e70108
Open AccessImpact of Multigene Panel Testing in High‐Risk Uveal Melanoma Patients
Germline genetic testing is increasingly incorporated into the care of patients with uveal melanoma, yet optimal testing strategies remain unclear. This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021 and 9/19/2025. Seventy individuals underwent clinical genetic testing, primarily via large multigene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes ( BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2 ). Among unrelated individuals, the positive rate was 13% (8/69). Excluding carrier genes, the rate was 10.1% (7/69). Eight patients would have been missed if only tested for BAP1 per American Society of Clinical Oncology (ASCO) 2024 recommendations. There was no association between tumor size, stage, and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, these findings support genetic counseling for multigene panel testing in high‐risk uveal melanoma patients. Further studies of the impact of germline variants on UM disease outcome are warranted.
- Open Access
- 17 March 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (2)
Patient-derived outcome assessment of knowledge, communication, and management in those diagnosed with BAP1-tumor predisposition syndrome
Germline pathogenic variants in BAP1 are associated with BAP1 tumor predisposition syndrome ( BAP1 -TPDS), and an increased risk for different cancers and preneoplastic lesions. This study assessed the degrees of patient knowledge of BAP1 -TPDS, patient-reported sharing of their genetic test results and diagnosis, and the degree of compliance with current management guidelines. A survey was sent to individuals with a germline pathogenic/likely pathogenic variant in BAP1 who are enrolled in a research registry at The Ohio State University. Knowledge about BAP1 -TPDS was assessed utilizing a modified scale (KnowGene). Participants were asked about communication surrounding BAP1 -TPDS with family members, and their current cancer surveillance. Forty-two (55%) subjects completed the survey with 25 (60%) having strong 80% knowledge of the syndrome, and 33 (79%) having at least 60% knowledge. All participants reported sharing their genetic result or diagnosis with at least one family member, primarily their first-degree relatives. Most of the cohort had undergone some recommended surveillance for BAP1 -TPDS. In conclusion, BAP1 -TPDS subjects are knowledgeable about the syndrome phenotype, highly communicative about their diagnosis with family members, and follow some recommended surveillance. Capturing patient-reported outcomes of BAP1 -TPDS subjects is crucial for understanding their need for further education, resources, or support.
- 17 March 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (2)
Open AccessPatient-derived outcome assessment of knowledge, communication, and management in those diagnosed with BAP1-tumor predisposition syndrome
Germline pathogenic variants in BAP1 are associated with BAP1 tumor predisposition syndrome ( BAP1 -TPDS), and an increased risk for different cancers and preneoplastic lesions. This study assessed the degrees of patient knowledge of BAP1 -TPDS, patient-reported sharing of their genetic test results and diagnosis, and the degree of compliance with current management guidelines. A survey was sent to individuals with a germline pathogenic/likely pathogenic variant in BAP1 who are enrolled in a research registry at The Ohio State University. Knowledge about BAP1 -TPDS was assessed utilizing a modified scale (KnowGene). Participants were asked about communication surrounding BAP1 -TPDS with family members, and their current cancer surveillance. Forty-two (55%) subjects completed the survey with 25 (60%) having strong 80% knowledge of the syndrome, and 33 (79%) having at least 60% knowledge. All participants reported sharing their genetic result or diagnosis with at least one family member, primarily their first-degree relatives. Most of the cohort had undergone some recommended surveillance for BAP1 -TPDS. In conclusion, BAP1 -TPDS subjects are knowledgeable about the syndrome phenotype, highly communicative about their diagnosis with family members, and follow some recommended surveillance. Capturing patient-reported outcomes of BAP1 -TPDS subjects is crucial for understanding their need for further education, resources, or support.
- Open Access
Multigene Panel Testing Outcomes in Patients with Uveal Melanoma: Implementation of National Guidelines
This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021-9/19/2025. Seventy individuals underwent clinical genetic testing, primarily via large multi-gene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes ( BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2) . Among unrelated individuals, the positive rate was12.9% (8/70). Excluding carrier genes, the rate was10% (7/70) Eight patients would have been missed if only tested for BAP1 per ASCO 2024 recommendations. There was no association between tumor size, stage and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, large panel testing, rather than BAP1 single gene testing, is recommended.
Open AccessMultigene Panel Testing Outcomes in Patients with Uveal Melanoma: Implementation of National Guidelines
This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021-9/19/2025. Seventy individuals underwent clinical genetic testing, primarily via large multi-gene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes ( BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2) . Among unrelated individuals, the positive rate was12.9% (8/70). Excluding carrier genes, the rate was10% (7/70) Eight patients would have been missed if only tested for BAP1 per ASCO 2024 recommendations. There was no association between tumor size, stage and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, large panel testing, rather than BAP1 single gene testing, is recommended.
- Open Access
High Frequency and Unique Subtypes of Meningioma in Patients with BAP1 Tumor Predisposition Syndrome
Background: BAP1 -tumor predisposition syndrome ( BAP1 -TPDS) is associated with four main cancers: uveal melanoma, cutaneous melanoma, malignant mesothelioma, and renal cell carcinoma. However, there are additional cancers found more rarely in BAP1 -TPDS patients. The aim of this study was to investigate the association, clinical, and pathologic characteristics of meningioma in BAP1 -TPDS. Methods: We conducted a retrospective chart review of meningiomas in two independent cohorts of patients with germline BAP1 pathogenic or likely pathogenic (P/LP) variants at The Ohio State University Wexner Medical Center and at the Memorial Sloan Kettering Cancer Center from October 1 st , 2010 date to April 21 st , 2025. Additionally, we conducted a literature review of meningioma case studies for individuals with germline BAP1 (P/LP) variants. Results: In a cohort of 237 subjects with BAP1 -TPDS, we identified 6.8% (16/237) with history of meningiomas. The average age of diagnosis was 45.8 years (17-71). For patients with available pathology, 61.5% (8/13) of the tumors were grade II/III. Patients with available tumor tissue 83.3% (5/6) showed evidence of BAP1 biallelic inactivation. Family history of meningioma was reported in 18.8% (3/16) of patients. Three cases of meningioma were identified during meningioma surveillance imaging. Published cases were consistent with the early age of onset, high-grade tumors, and clinical phenotype of tumors. Conclusions: This study provides additional evidence that high-grade brain and spinal meningiomas are part of the clinical spectrum of BAP1 -TPDS. Craniospinal imaging surveillance in the BAP1 -TPDS population should be considered starting around puberty, enabling early detection and management for individuals with BAP1 -TPDS. Key Points: High frequency of patients in our BAP1-TPDS cohort had meningiomas (6.8%) BAP1-TPDS meningiomas had rhabdoid and papillary histologic subtypes and high WHO grades These patients were diagnosed at a younger age compared to the average population There was a female predominance of meningioma in BAP1-TPDS patients BAP1-TPDS related meningiomas are at risk for higher rates of local recurrence, particularly rhabdoid histology Importance of the Study: BAP1-tumor predisposition syndrome ( BAP1 -TPDS) is a rare syndrome which is associated with four cancers: uveal melanoma, cutaneous melanoma, malignant mesothelioma, and renal cell carcinoma. However, our group has observed additional cancers in these patients, including meningioma. Here, we present a retrospective chart review of 16 patients with germline pathogenic BAP1 variants and meningioma, representing 6.8% of our entire cohort of BAP1 -TPDS cases. We report that BAP1-TPDS patients are at higher risk of developing high-grade meningiomas and are diagnosed at an earlier age than the general population. Three meningiomas and one meningothelial cyst were observed during surveillance imaging in asymptomatic patients. Patient and family cancer history included other BAP1 -TPDS associated cancers, but only three patients had relatives with meningioma. Our findings indicate a need for routine craniospinal imaging in BAP1 -TPDS patients, and surveillance should include patients without family history of meningioma and patients under the age of 30.
Open AccessHigh Frequency and Unique Subtypes of Meningioma in Patients with BAP1 Tumor Predisposition Syndrome
Background: BAP1 -tumor predisposition syndrome ( BAP1 -TPDS) is associated with four main cancers: uveal melanoma, cutaneous melanoma, malignant mesothelioma, and renal cell carcinoma. However, there are additional cancers found more rarely in BAP1 -TPDS patients. The aim of this study was to investigate the association, clinical, and pathologic characteristics of meningioma in BAP1 -TPDS. Methods: We conducted a retrospective chart review of meningiomas in two independent cohorts of patients with germline BAP1 pathogenic or likely pathogenic (P/LP) variants at The Ohio State University Wexner Medical Center and at the Memorial Sloan Kettering Cancer Center from October 1 st , 2010 date to April 21 st , 2025. Additionally, we conducted a literature review of meningioma case studies for individuals with germline BAP1 (P/LP) variants. Results: In a cohort of 237 subjects with BAP1 -TPDS, we identified 6.8% (16/237) with history of meningiomas. The average age of diagnosis was 45.8 years (17-71). For patients with available pathology, 61.5% (8/13) of the tumors were grade II/III. Patients with available tumor tissue 83.3% (5/6) showed evidence of BAP1 biallelic inactivation. Family history of meningioma was reported in 18.8% (3/16) of patients. Three cases of meningioma were identified during meningioma surveillance imaging. Published cases were consistent with the early age of onset, high-grade tumors, and clinical phenotype of tumors. Conclusions: This study provides additional evidence that high-grade brain and spinal meningiomas are part of the clinical spectrum of BAP1 -TPDS. Craniospinal imaging surveillance in the BAP1 -TPDS population should be considered starting around puberty, enabling early detection and management for individuals with BAP1 -TPDS. Key Points: High frequency of patients in our BAP1-TPDS cohort had meningiomas (6.8%) BAP1-TPDS meningiomas had rhabdoid and papillary histologic subtypes and high WHO grades These patients were diagnosed at a younger age compared to the average population There was a female predominance of meningioma in BAP1-TPDS patients BAP1-TPDS related meningiomas are at risk for higher rates of local recurrence, particularly rhabdoid histology Importance of the Study: BAP1-tumor predisposition syndrome ( BAP1 -TPDS) is a rare syndrome which is associated with four cancers: uveal melanoma, cutaneous melanoma, malignant mesothelioma, and renal cell carcinoma. However, our group has observed additional cancers in these patients, including meningioma. Here, we present a retrospective chart review of 16 patients with germline pathogenic BAP1 variants and meningioma, representing 6.8% of our entire cohort of BAP1 -TPDS cases. We report that BAP1-TPDS patients are at higher risk of developing high-grade meningiomas and are diagnosed at an earlier age than the general population. Three meningiomas and one meningothelial cyst were observed during surveillance imaging in asymptomatic patients. Patient and family cancer history included other BAP1 -TPDS associated cancers, but only three patients had relatives with meningioma. Our findings indicate a need for routine craniospinal imaging in BAP1 -TPDS patients, and surveillance should include patients without family history of meningioma and patients under the age of 30.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (10) , 1374-1376
Overcoming Barriers to Genetic Testing in Prostate Cancer Care
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (10) , 1374-1376
Overcoming Barriers to Genetic Testing in Prostate Cancer Care
- Open Access
- 16 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e010417
Germline whole-exome sequencing reveals FOXP3-related gene variants conferring urinary cancer susceptibility and associated with immune escape
Background: The heritability of urinary tract cancer (UTC) remains unexplained by known pathogenic germline variants, and the influence of germline variants on treatment response to immune checkpoint inhibition (ICI) has yet to be fully elucidated. Methods: In this case–control study, we performed a germline whole-exome sequencing of 810 UTC patients from the Oncology Research Information Exchange Network. A rare-variant burden test was conducted on the 810 patients and 2354 healthy controls from the Centre d'Etudes du Polymorphisme Humain families, the University of Utah Heritage 1000 Projects, and the 1000 Genomes Project, stratified into discovery and confirmation sets. We used a gene set-based rare-variant association test (GSRVAT) with near-match confirmation, testing for the association of pathways with UTC susceptibility and accounting for multiple testing. We then studied the impact of the identified pathways on tumor biology and clinical course among the 810 cases by analyzing their tumor exomes, transcriptomes, and clinical features. Results: GSRVAT revealed forkhead box p3 (FOXP3) as a susceptibility pathway in 16% of patients with UTC, with an epistasis with DNA mismatch repair. Carriers of germline truncating variants in FOXP3-related susceptibility genes exhibited decreased tumor FOXP3 expression levels, which were associated with a cold tumor microenvironment and significantly reduced overall and progression-free survival following ICI. Conclusions: Germline variants in a set of FOXP3-related genes confer inherent susceptibility to UTC and contribute to resistance against ICI. The immune-evading trait resulting from these variants and the downregulation of FOXP3 expression introduce a novel avenue for personalized medicine through germline and tumor sequencing.
- 16 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e010417
Open AccessGermline whole-exome sequencing reveals FOXP3-related gene variants conferring urinary cancer susceptibility and associated with immune escape
Background: The heritability of urinary tract cancer (UTC) remains unexplained by known pathogenic germline variants, and the influence of germline variants on treatment response to immune checkpoint inhibition (ICI) has yet to be fully elucidated. Methods: In this case–control study, we performed a germline whole-exome sequencing of 810 UTC patients from the Oncology Research Information Exchange Network. A rare-variant burden test was conducted on the 810 patients and 2354 healthy controls from the Centre d'Etudes du Polymorphisme Humain families, the University of Utah Heritage 1000 Projects, and the 1000 Genomes Project, stratified into discovery and confirmation sets. We used a gene set-based rare-variant association test (GSRVAT) with near-match confirmation, testing for the association of pathways with UTC susceptibility and accounting for multiple testing. We then studied the impact of the identified pathways on tumor biology and clinical course among the 810 cases by analyzing their tumor exomes, transcriptomes, and clinical features. Results: GSRVAT revealed forkhead box p3 (FOXP3) as a susceptibility pathway in 16% of patients with UTC, with an epistasis with DNA mismatch repair. Carriers of germline truncating variants in FOXP3-related susceptibility genes exhibited decreased tumor FOXP3 expression levels, which were associated with a cold tumor microenvironment and significantly reduced overall and progression-free survival following ICI. Conclusions: Germline variants in a set of FOXP3-related genes confer inherent susceptibility to UTC and contribute to resistance against ICI. The immune-evading trait resulting from these variants and the downregulation of FOXP3 expression introduce a novel avenue for personalized medicine through germline and tumor sequencing.
- 10 July 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (12) , e64176
First Report of BAP1 ‐Associated Polyposis
BAP1 Tumor Predisposition Syndrome ( BAP1 ‐TPDS) is caused by germline pathogenic variants in the BAP1 gene and has been associated with uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and other benign cutaneous lesions. Adenomatous colon polyposis has not previously been reported as part of BAP1 ‐TPDS. We report two patients with unexplained adenomatous oligopolyposis and germline BAP1 pathogenic variants. To determine if BAP1 had a role in polypogenesis, we performed somatic mutational analysis on multiple polyps from both patients ( n = 8 total polyps tested). In every polyp tested, we found evidence of second BAP1 allele inactivation, including second somatic BAP1 mutations. Further, we did not detect any mutations in the commonly identified adenomatous polyposis pathway drivers, APC , CTNNB1 , or other WNT/β‐catenin. We did not detect somatic BAP1 mutations in any adenomatous polyps from patients without germline BAP1 pathogenic variants ( n = 151 patients), highlighting the specificity of somatic BAP1 second hit mutations in BAP1 germline carrier polyps. Our findings strongly support that the polyps in these patients were caused by BAP1 , and that adenomatous oligopolyposis is a part of the BAP1 ‐TPDS tumor spectrum. Further work is needed to characterize the penetrance of this new BAP1 ‐associated phenotype.
- 10 July 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (12) , e64176
First Report of BAP1 ‐Associated Polyposis
BAP1 Tumor Predisposition Syndrome ( BAP1 ‐TPDS) is caused by germline pathogenic variants in the BAP1 gene and has been associated with uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and other benign cutaneous lesions. Adenomatous colon polyposis has not previously been reported as part of BAP1 ‐TPDS. We report two patients with unexplained adenomatous oligopolyposis and germline BAP1 pathogenic variants. To determine if BAP1 had a role in polypogenesis, we performed somatic mutational analysis on multiple polyps from both patients ( n = 8 total polyps tested). In every polyp tested, we found evidence of second BAP1 allele inactivation, including second somatic BAP1 mutations. Further, we did not detect any mutations in the commonly identified adenomatous polyposis pathway drivers, APC , CTNNB1 , or other WNT/β‐catenin. We did not detect somatic BAP1 mutations in any adenomatous polyps from patients without germline BAP1 pathogenic variants ( n = 151 patients), highlighting the specificity of somatic BAP1 second hit mutations in BAP1 germline carrier polyps. Our findings strongly support that the polyps in these patients were caused by BAP1 , and that adenomatous oligopolyposis is a part of the BAP1 ‐TPDS tumor spectrum. Further work is needed to characterize the penetrance of this new BAP1 ‐associated phenotype.
- Open Access
- 1 July 2025
- Published by SAGE Publications in Kidney Cancer
- Vol. 9, 37-44
Assessing genetic and urologic providers on renal screening recommendations for individuals with a familial renal cancer risk
Background: While hereditary renal cell carcinoma (RCC) syndromes account for up to 16% of RCC cases and have screening guidelines; no screening recommendations exist for individuals with family history of RCC and negative genetic testing (familial RCC risk). Objective: This study aimed to assess current practices regarding screening recommendations for patients with familial RCC risk, evaluate the perceived need for formalized screening guidelines, and identify optimal clinician involvement for developing such guidelines. Methods: We surveyed healthcare providers who provide medical care for RCC patients, assessing current familial RCC screening practices, the need for and process of developing empiric risk guidelines, and case-based scenarios to understand current practice. This IRB-approved survey was distributed using listservs, professional connections, and snowball methods. Descriptive statistics and qualitative coding were used to analyze the data. Results: Seventy healthcare providers participated, primarily genetic counselors (n = 46; 66%) and medical oncologists (n = 11; 16%). Respondents indicated that: 1) screening guidelines are needed (n = 64; 91%) for familial RCC risk; 2) RCC patients inquired about the risk of RCC to family members after receiving negative genetic test results (n = 59; 84%, sometimes, often, or always); and 3) asked about screening recommendations for family members with similar frequency (n = 56, 80%). Respondents varied on the optimal screening mechanism and indications for screening unaffected relatives of RCC patients. Conclusions: Our findings show providers need screening guidelines to address patient inquiries, guide clinical management, and improve insurance coverage. Respondents agreed that there was a need for a multi-disciplinary team to develop standardized recommendations.
- 1 July 2025
- Published by SAGE Publications in Kidney Cancer
- Vol. 9, 37-44
Open AccessAssessing genetic and urologic providers on renal screening recommendations for individuals with a familial renal cancer risk
Background: While hereditary renal cell carcinoma (RCC) syndromes account for up to 16% of RCC cases and have screening guidelines; no screening recommendations exist for individuals with family history of RCC and negative genetic testing (familial RCC risk). Objective: This study aimed to assess current practices regarding screening recommendations for patients with familial RCC risk, evaluate the perceived need for formalized screening guidelines, and identify optimal clinician involvement for developing such guidelines. Methods: We surveyed healthcare providers who provide medical care for RCC patients, assessing current familial RCC screening practices, the need for and process of developing empiric risk guidelines, and case-based scenarios to understand current practice. This IRB-approved survey was distributed using listservs, professional connections, and snowball methods. Descriptive statistics and qualitative coding were used to analyze the data. Results: Seventy healthcare providers participated, primarily genetic counselors (n = 46; 66%) and medical oncologists (n = 11; 16%). Respondents indicated that: 1) screening guidelines are needed (n = 64; 91%) for familial RCC risk; 2) RCC patients inquired about the risk of RCC to family members after receiving negative genetic test results (n = 59; 84%, sometimes, often, or always); and 3) asked about screening recommendations for family members with similar frequency (n = 56, 80%). Respondents varied on the optimal screening mechanism and indications for screening unaffected relatives of RCC patients. Conclusions: Our findings show providers need screening guidelines to address patient inquiries, guide clinical management, and improve insurance coverage. Respondents agreed that there was a need for a multi-disciplinary team to develop standardized recommendations.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400946
Germline POT1 Variants in a Pan-Cancer Cohort
PURPOSE: Germline likely pathogenic and pathogenic variants (LPV/PVs) in POT1 have been associated with an increased risk of various cancers including angiosarcoma, melanoma, glioma, thyroid cancer, and chronic lymphocytic leukemia (CLL). However, to date, most of the published data regarding POT1 PVs involve cohorts of patients selected for specific cancer types, or stem from commercial laboratory cohorts from patients selected for germline clinical testing, which may cause ascertainment biases. The objective was to identify germline POT1 variants in a pan-cancer cohort and describe the associated phenotypes. METHODS: Germline exome data available for 19,315 patients with cancer from the Oncology Research Information Exchange Network (ORIEN) were assessed for POT1 LPV/PV. Data regarding cancer diagnoses were obtained for those with and without POT1 variants. Associations were assessed. RESULTS: POT1 LPV/PVs were identified in 23 patients. The cancer types seen in more than one patient include CLL (n = 7), papillary thyroid cancer (PTC, n = 5), colorectal cancer (n = 3), lung cancer (n = 3), glioblastoma (n = 2), and neuroendocrine tumors (n = 2). Compared with POT1 -negative patients, those with POT1 LPV/PVs were 5.5-fold more likely to be diagnosed with PTC (95% CI, 1.9 to 15.1; P = .004) and 16.6-fold more likely to be diagnosed with CLL (95% CI, 6.4 to 41.9; P < .001). Patients with POT1 LPV/PVs had a younger median age of first cancer diagnosis compared with POT1 -negative patients ( P = .008). CONCLUSION: To our knowledge, this study is the largest investigation of POT1 germline variants in a pan-cancer cohort. We identify and confirm specific associations with CLL and PTC in this cohort. Differences in results between analysis of largely unselected cohorts compared with clinical testing cohorts highlight the need to study gene-cancer associations in more unselected populations.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400946
Germline POT1 Variants in a Pan-Cancer Cohort
PURPOSE: Germline likely pathogenic and pathogenic variants (LPV/PVs) in POT1 have been associated with an increased risk of various cancers including angiosarcoma, melanoma, glioma, thyroid cancer, and chronic lymphocytic leukemia (CLL). However, to date, most of the published data regarding POT1 PVs involve cohorts of patients selected for specific cancer types, or stem from commercial laboratory cohorts from patients selected for germline clinical testing, which may cause ascertainment biases. The objective was to identify germline POT1 variants in a pan-cancer cohort and describe the associated phenotypes. METHODS: Germline exome data available for 19,315 patients with cancer from the Oncology Research Information Exchange Network (ORIEN) were assessed for POT1 LPV/PV. Data regarding cancer diagnoses were obtained for those with and without POT1 variants. Associations were assessed. RESULTS: POT1 LPV/PVs were identified in 23 patients. The cancer types seen in more than one patient include CLL (n = 7), papillary thyroid cancer (PTC, n = 5), colorectal cancer (n = 3), lung cancer (n = 3), glioblastoma (n = 2), and neuroendocrine tumors (n = 2). Compared with POT1 -negative patients, those with POT1 LPV/PVs were 5.5-fold more likely to be diagnosed with PTC (95% CI, 1.9 to 15.1; P = .004) and 16.6-fold more likely to be diagnosed with CLL (95% CI, 6.4 to 41.9; P < .001). Patients with POT1 LPV/PVs had a younger median age of first cancer diagnosis compared with POT1 -negative patients ( P = .008). CONCLUSION: To our knowledge, this study is the largest investigation of POT1 germline variants in a pan-cancer cohort. We identify and confirm specific associations with CLL and PTC in this cohort. Differences in results between analysis of largely unselected cohorts compared with clinical testing cohorts highlight the need to study gene-cancer associations in more unselected populations.